Clinical stage pharmaceutical company Promontory Therapeutics Inc on Tuesday announced a successful in-person End of Phase 2 (EOP2) Meeting with the US Food and Drug Administration (FDA), enabling the company to prepare and submit a registrational Phase 3 study of PT-112 monotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
In the meeting, the FDA agreed with the proposed dosing regimen for use in a prospective, randomised controlled Phase 3 registrational study. The company will now prepare its full Phase 3 study submission for final review on the basis of the FDA's guidance, and conduct similar meetings with international regulatory authorities.
The proof of concept and dose optimisation Phase 2 study of PT-112 monotherapy in advanced mCRPC was conducted in the United States and France, and included three randomised dosing arms of PT-112.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval